1. Clinical Implications of CD4+CD25+Foxp3+Regulatory T Cell Frequencies After CHP-MAGE-A4 Cancer Vaccination
- Author
-
Toshihiko Kuwatani, Takahiro Tsuchikawa, Toshiaki Shichinohe, Kengo Miyauchi, Hiroshi Shiku, Yoshihiro Miyahara, Masataka Wada, Shinichi Kageyama, Takehiro Abiko, Noriaki Kyogoku, Satoshi Hirano, Shintaro Takeuchi, and Hiroaki Ikeda
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Regulatory T cell ,Cancer ,FOXP3 ,chemical and pharmacologic phenomena ,General Medicine ,medicine.disease ,Clinical trial ,Vaccination ,Immune system ,medicine.anatomical_structure ,Internal medicine ,Medicine ,Cancer vaccine ,IL-2 receptor ,business - Abstract
Background/aim The aim of this study was to explore whether the treatment effect or immune response to a cancer vaccine can be predicted by the percentage of CD4+CD25+Foxp3+ regulatory T cells (Tregs) in peripheral blood mononuclear cells (PBMCs) after vaccination. Patients and methods Sixteen patients (9 men, 7 women; median age 61.5 years) enrolled in the CHP-MAGE-A4 cancer vaccine clinical trial who had a fixed dose (300 μg of CHP-MAGE-A4 cancer vaccine and 0.5 Klinische Einheit (KE) of OK432 and received at least four vaccinations were investigated. Safety, immune response, and clinical effects were assessed before and after the cancer vaccination. Results Treg ratios that remained low both before and after vaccination were associated with a good prognosis, and a low Treg/CD4 lymphocyte ratio 7-weeks after the initial vaccination was correlated with a better prognosis. Conclusion The Treg ratio following vaccination appears to have some utility for predicting patient prognosis.
- Published
- 2018
- Full Text
- View/download PDF